Drug Profile
Nalbuphine extended release - Trevi Therapeutics
Alternative Names: Haduvio; Nalbuphine ER; Nalbuphine extended-release; PW-4142; T 111Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Penwest Pharmaceuticals
- Developer Endo Pharmaceuticals; MentiNova; Rutgers; Trevi Therapeutics
- Class Analgesics; Antipruritics; Antitussives; Morphinans; Opioid analgesics; Skin disorder therapies; Small molecules
- Mechanism of Action Opioid kappa receptor agonists; Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Prurigo nodularis; Pruritus
- Phase II Cough
- No development reported Drug-induced dyskinesia
- Discontinued Pain
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Drug-induced-dyskinesia in USA (PO, Controlled release)
- 07 Mar 2024 Phase-II clinical trials in Cough in Australia, Germany, Netherlands, Spain (PO) (NCT05964335)
- 07 Mar 2024 Trevi Therapeutics initiates a Phase-II CORAL clinical trials in Cough in Canada (PO) (NCT05964335)